Literature DB >> 9850095

Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.

O Katoh1, T Takahashi, T Oguri, K Kuramoto, K Mihara, M Kobayashi, S Hirata, H Watanabe.   

Abstract

We reported previously that vascular endothelial growth factor (VEGF) inhibits the apoptotic death of hematopoietic cells that is induced by exposure to ionizing radiation (O. Katoh et al., Cancer Res., 55: 5687-5692, 1995). In this study, we show that VEGF also inhibits apoptotic cell death that is induced by exposure to the chemotherapeutic drugs etoposide and doxorubicin. To elucidate the molecular mechanisms underlying this inhibitory effect of VEGF, we examined expression levels of BCL2 family proteins in CMK86, a human leukemia cell line, after treatment with VEGF. Northern blotting and immunoblotting analyses revealed that the expression level of MCL1, a member of the BCL2 family, was increased by VEGF. Moreover, to examine the effects of MCL1 on apoptotic cell death induced by exposure to etoposide, we generated a clonal U937 myeloid leukemia cell line transfected with vectors that promoted the constitutive expression of MCL1. MCL1 decreased the caspase 3 activity induced by exposure to etoposide and increased the viability of the transfected cells after etoposide exposure. Therefore, MCL1 may be involved in the inhibitory effect of VEGF on apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Authors:  De-Chao Yu; Jung-Sun Lee; Ji Young Yoo; Hyewon Shin; Hongxin Deng; Yuquan Wei; Chae-Ok Yun
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

4.  Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis.

Authors:  K M Schubert; V Duronio
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

5.  Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance?

Authors:  K E Hovinga; L J A Stalpers; C van Bree; M Donker; J J C Verhoeff; H M Rodermond; D A Bosch; W R van Furth
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

6.  Multilineage embryonic hematopoiesis requires hypoxic ARNT activity.

Authors:  D M Adelman; E Maltepe; M C Simon
Journal:  Genes Dev       Date:  1999-10-01       Impact factor: 11.361

7.  Up-regulation of VEGF and its receptor in refractory leukemia cells.

Authors:  Lei Wang; Wenjun Zhang; Yi Ding; Bing Xiu; Ping Li; Yan Dong; Qi Zhu; Aibin Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

8.  Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.

Authors:  Ying Wang; Lu Huang; Yunmei Yang; Liqian Xu; Ji Yang; Yue Wu
Journal:  Mol Biol Rep       Date:  2013-03-04       Impact factor: 2.316

Review 9.  The role of VEGF in normal and neoplastic hematopoiesis.

Authors:  Hans-Peter Gerber; Napoleone Ferrara
Journal:  J Mol Med (Berl)       Date:  2002-12-14       Impact factor: 4.599

Review 10.  Hematopoietic stem cell niche maintenance during homeostasis and regeneration.

Authors:  Avital Mendelson; Paul S Frenette
Journal:  Nat Med       Date:  2014-08       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.